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Recent studies have shown that mutations at amino-acid 482 in the ABCG2 gene affect the substrate specificity of the protein. To
delineate the effects of these mutations clearly, human embryonic kidney cells (HEK-293) were stably transfected with wild-type
482R or mutant 482G and 482T ABCG2. By flow cytometry, mitoxantrone, BODIPY-prazosin, and Hoechst 33342 were found to be
substrates of all ABCG2 proteins, while rhodamine 123, daunorubicin, and LysoTracker Green were transported only by mutant
ABCG2. In cytotoxicity assays, all ABCG2 proteins conferred high levels of resistance to mitoxantrone, SN-38, and topotecan, while
mutant ABCG2 also exhibited a gain of function for mitoxantrone as they conferred a four-fold greater resistance compared to wild
type. Cells transfected with mutant ABCG2 were 13- to 71- fold resistant to the P-glycoprotein substrates doxorubicin, daunorubicin,
epirubicin, bisantrene, and rhodamine 123 compared to cells transfected with wild-type ABCG2, which were only three- to four-fold
resistant to these compounds. ABCG2 did not confer appreciable resistance to etoposide, taxol or the histone deacetylase inhibitor
depsipeptide. None of the transfected cell lines demonstrated resistance to flavopiridol despite our previous observation that
ABCG2-overexpressing cell lines are cross-resistant to the drug. Recently reported inhibitors of ABCG2 were evaluated and 50mM
novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially. The studies presented
here serve to underscore the importance of amino-acid 482 in defining the substrate specificity of the ABCG2 protein and raise the
possibility that amino-acid 482 mutations in human cancers could affect the clinical application of antagonists for ABCG2.
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ABCG2 is an ATP-binding cassette half-transporter (Allikmets et al,
1998; Doyle et al, 1998; Miyake et al, 1999) that has been shown to
confer resistance to a variety of chemotherapeutic agents including
mitoxantrone (Brangi et al, 1999; Litman et al, 2000); the
camptothecins topotecan (Maliepaard et al, 1999; Yang et al,
2000) and SN-38 (Kawabata et al, 2001); doxorubicin (Chen et al,
1990); and flavopiridol (Robey et al, 2001b). Cells overexpressing
wild-type ABCG2 with an arginine at amino-acid 482 have been
shown by flow cytometric analysis to transport mitoxantrone,
while those overexpressing ABCG2 with a threonine or glycine at
position 482 (R482G, R482T) transported mitoxantrone and also
exhibited a gain in function with the transport of rhodamine 123
and daunorubicin (Honjo et al, 2001). In Cytotoxicity assays, cells
overexpressing any of the ABCG2 proteins are resistant to
mitoxantrone, topotecan, and SN-38, while cells overexpressing
mutant ABCG2 are additionally resistant to the anthracyclines.
Although these phenotypic differences have been well described in
selected cell lines, careful studies in transfected cells were needed
to exclude bias due to other mechanisms of resistance in selected
cell lines.
A similar situation was recently described for the mouse
homologue, Abcg2. Allen et al (1999) reported overexpression of
Abcg2 in mouse fibroblast cell lines lacking functional Mdr1a,
Mdr1b, and Mrp1, which were selected in mitoxantrone, doxor-
ubicin, or topotecan. Greater doxorubicin resistance was observed
in the cells selected in doxorubicin compared to those selected in
mitoxantrone or topotecan. Upon sequencing Abcg2 in these cell
lines and two other fibroblast cell lines selected in doxorubicin, it
was noted that the arginine at position 482 in wild-type Abcg2 was
mutated to a methionine or serine. Expression of the mutant
Abcg2 proteins conferred greater resistance to the anthracyclines
as well as the ability to transport rhodamine 123 (Allen et al, 2002).
Allen suggested that the 482 residue represented a hot spot for
mutation in ABCG2. Subsequent to these studies, an arginine to
methionine mutation was also described in a selected human cell
line (Wang et al, 2003).
To characterize precisely the cross-resistance profile conferred
by the wild-type and mutant ABCG2 proteins, we transfected
human embryonic kidney (HEK-293) cells with 482R, 482T, or
482G ABCG2. In transfected cell lines expressing comparable levels
of ABCG2, we tested the ability of the transfectants to transport
fluorescent compounds reported to be substrates of the half-
transporter, and performed killing curves with chemotherapeutic
agents reported to be effluxed by ABCG2 to determine the cross-
resistance profile conferred by each of the ABCG2 proteins.
The interactions of the recently reported ABCG2 antagonists
novobiocin (Doyle et al, 2002; Shiozawa et al, 2002), b-estradiol,
and estrone (Imai et al, 2002) with wild-type and mutant ABCG2
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swere also examined. The results presented here demonstrate
amino-acid 482 to be significant in determining the effectiveness of
ABCG2 antagonists as well as the ability to transport selected
antineoplastic drugs.
MATERIALS AND METHODS
Chemicals
The fluorescent compounds LysoTracker Green DND-26 and
BODIPY-prazosin were purchased from Molecular Probes (Eu-
gene, OR, USA). Flavopiridol, topotecan, depsipeptide, and
epirubicin were obtained from the National Cancer Institute Drug
Screen. Mitoxantrone, daunorubicin, doxorubicin, Hoechst 33342,
rhodamine 123, novobiocin, estrone, and b-estradiol were
purchased from Sigma Chemical Co. (St Louis, MO, USA).
Bisantrene was a gift from Dr Lee Greenberger (Wyeth-Ayerst).
Fumitremorgin C (FTC) was synthesised by Thomas McCloud,
Developmental Therapeutics Program, Natural Products Extrac-
tion Laboratory, National Institutes of Health (Bethesda, MD,
USA).
Establishment of stable transfectants
HEK-293 cells were transfected with either empty pcDNA3 vector
(Invitrogen, Carlsbad, CA, USA) or pcDNA3 vector containing full-
length ABCG2 coding either an arginine, threonine or glycine for
amino-acid 482. Expression of ABCG2 in the transfectants was
enforced by selection in G418 (Invitrogen, Carlsbad, CA, USA).
Stable transfectants were maintained in Eagle’s minimum essential
medium (ATCC, Manassas, VA, USA) supplemented with 10%
FCS, penicillin, and streptomycin with G418 at a concentration of
2mgml
1. Clones were preliminarily screened for ABCG2 expres-
sion by examining the ability of the cells to efflux BODIPY-
prazosin in a flow cytometry-based assay. The ABCG2 sequence
was subsequently verified in the clones examined here.
RNA isolation and Northern blot analysis
RNA was extracted from cells using RNA STAT-60 (Tel-Test Inc.,
Friendswood, TX, USA) according to the manufacturer’s instruc-
tions. Northern blot analysis was performed using a riboprobe
generated from the first 662bp of ABCG2 subcloned into a pCRII-
TOPO vector (Invitrogen, Carlsbad, CA, USA).
Western blot analysis
Microsomal membrane fractions (30mg) were subjected to
electrophoresis and transferred to nitrocellulose membranes as
previously described (Robey et al, 2001b). Blots were probed with
the monoclonal anti-BCRP antibody BXP-21 (Maliepaard et al,
2001) (Kamiya Biomedical, Seattle WA, USA) as previously
described (Litman et al, 2000).
Flow cytometry
Flow cytometry assays were performed as previously described
(Robey et al, 2001a). Briefly, cells were trypsinised, resuspended in
complete media (phenol red-free IMEM with 10% fetal calf serum)
containing 20mM mitoxantrone, 5mgml
1 daunorubicin, 250nM
BODIPY-prazosin, 0.5mgml
1 rhodamine 123, 250nM LysoTracker
Green DND-26, or 10mM Hoechst 33342 with or without 10mM of
the ABCG2 blocker, FTC, and incubated for 30min at 371Ci n5 %
CO2. FTC has been reported to be a specific blocker of ABCG2
(Rabindran et al, 1998, Rabindran et al, 2000), and we assumed
10mM FTC afforded complete prevention of ABCG2-mediated
efflux based on previous results. In studies with reported ACBG2
antagonists, cells were incubated with 250nM BODIPY-prazosin
alone or with various concentrations of the inhibitors. Cells were
then washed once in cold complete medium and then incubated
for 1h at 371C in substrate-free media continuing with or without
10mM FTC or the described concentrations of the other ABCG2
inhibitors to generate the efflux and FTC/efflux histograms (or
inhibitor/efflux histograms), respectively. Subsequently, cells were
washed twice with cold DPBS and placed on ice in the dark until
analysed. FTC/efflux–efflux values, calculated as the difference in
mean channel numbers between the FTC/efflux and efflux peaks,
were generated for each cell line with each fluorescent substrate.
Cells were analysed either on a FACSort flow cytometer equipped
with both a 488nm argon laser and a 635nm red diode laser or a
FACSVantage flow cytometer equipped with a 360nM UV laser to
detect Hoechst 33342 fluorescence. For all samples, at least 10000
events were collected. Debris was eliminated by gating on forward
vs side scatter and dead cells were excluded based on propidium
iodide staining.
For studies with the anti-ABCG2 antibody, 5D3, cells were
trypsinised and resuspended in DPBS with 2% BSA to which was
added phycoerythrin-conjugated 5D3 (eBioscience, San Diego, CA,
USA) or phycoerythrin-conjugated mouse IgG. The cells were
incubated with antibody for 30min at room temperature, washed
twice with DPBS and kept in the dark until analysed.
Cytotoxicity assays
The cytotoxocity assays performed were based on the previously
described sulphorhodamine B assay (Skehan et al, 1990). Cells
were plated in flat-bottom 96-well plates at a density of 2000 cells
per well and allowed to attach for 24h at 371Ci n5 %C O 2.
Chemotherapeutic agents at various concentrations were added to
the cells and the plates were allowed to incubate for 96h at 371Ci n
5% CO2. Subsequently, cells were fixed in 12.5% trichloroacetic
acid and then stained with sulphorhodamine B solution (0.4%
sulphorhodamine B wv
1 in 1% acetic acid). Optical densities
were read on a Bio-Rad plate reader at an absorbance of 540nm.
Each concentration was tested in triplicate and controls were
performed in replicates of eight.
RESULTS
Expression of ABCG2 in HEK-293 cells
HEK-293 cells were transfected with the ABCG2 gene and screened
based on BODIPY-prazosin transport (data not shown). From the
positive clones obtained, two clones transfected with each ABCG2
gene (482G-1, 482G-2, 482R-2, 482R-5, 482T-7, 482T-10) and one
clone transfected with empty vector (pcDNA3-10) were selected
and RNA was extracted. Northern blotting was performed using
20mg total RNA. As shown in Figure 1A, all clones transfected with
ABCG2 have enforced expression of the ABCG2 gene at the RNA
level; in the cell line transfected with empty vector, no ABCG2 RNA
was detected. Western blotting was performed on 30mg membrane
protein isolated from the seven cell lines and comparable protein
expression was observed (Figure 1B). Serial dilutions of protein
from the transfectants used in cytotoxicity assays revealed about a
two-fold higher level in wild-type-expressing cells (482R-2) than
the mutant-expressing cells (482G-1, 482T-10) as seen in Figure 1C.
The seven cell lines shown in Figure 1A were then incubated with
an anti-ABCG2 monoclonal antibody, clone 5D3 (Zhou et al, 2001),
to measure the expression of ABCG2 on the cell surface by flow
cytometry. All stably transfected cell lines demonstrated compar-
able expression of ABCG2 on the cell surface, with the empty
vector transfected cells expressing no ABCG2 (Figure 1D); the
difference in channel numbers between cells incubated with
negative control antibody and the anti-ABCG2 antibody 5D3 are
given in Table 1. Despite higher ABCG2 expression at the RNA
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found in all of the transfectants. The sequence of the transfected
ABCG2 was confirmed in the six positive clones.
Transport of fluorescent substrates by ABCG2-transfected
HEK-293 cells
The amino acid at position 482 has been found to be predictive for
the ability of ABCG2 to transport fluorescent substrates (Honjo
et al, 2001). Representative histograms for rhodamine 123,
daunorubicin, mitoxantrone, BODIPY-prazosin, and LysoTracker
Green are shown in Figure 2. Here the dotted lines represented the
accumulation of the substrate in the presence of the ABCG2
inhibitor fumitremorgin C, while the solid line represents the
accumulation without inhibitor. Reduced accumulation that is
increased by FTC is present to varying degrees in the 482G and
482T mutants for all of the substrates. In contrast, those vectors
carrying the wild-type (482R) ABCG2 showed evidence of
transport only of mitoxantrone and BODIPY-prazosin. FTC/
efflux–efflux values for BODIPY-prazosin, rhodamine 123, dau-
norubicin, LysoTracker Green DND-26, and mitoxantrone were
calculated for each cell line. We have previously shown that FTC-
inhibitable mitoxantrone or BODIPY-prazosin efflux (FTC/efflux–
efflux value) is proportional to the expression of ABCG2 in cell
lines (Robey et al, 2001a). The results are summarised in Table 1;
negative FTC/efflux–efflux values were given the value of zero.
FTC/efflux–efflux values for mitoxantrone and BODIPY-prazosin
were comparable among the transfected cell lines. However, efflux
of rhodamine 123, LysoTracker Green and daunorubicin is only
observed in HEK-293 cells transfected with mutant 482G or 482T
ABCG2. As the dye Hoechst 33342 has recently been shown to be a
substrate of ABCG2 (Zhou et al, 2001; Kim et al, 2002; Scharenberg
et al, 2002), the ability of the three ABCG2 proteins to transport the
compound was evaluated and confirmed for all three proteins.
None of the fluorescent compounds was transported by the cell
line transfected with empty vector (data not shown).
Sensitivity of HEK-293 cells transfected with wild-type or
mutant ABCG2 to antineoplastic agents
The 4-day cytotoxicity assays were performed on the empty vector
transfected cells as well as the 482G-1, 482R-2, and 482T-10
transfected clones. The results are summarised in Table 2;
representative curves for some of the compounds tested are
shown in Figure 3. In agreement with previous reports, HEK-293
cells transfected with any of the ABCG2 genes exhibited high levels
of resistance to mitoxantrone compared to empty vector-
transfected cells; however, IC50 values for 482G-1 and 482T-10,
543 and 457nM respectively, were about four-fold higher than for
the 482R-2 cells, 107nM. When cytotoxicity experiments were
performed with mitoxantrone on another set of clones, 482G-2,
482R-5, and 482T-7, the HEK-293 cells expressing either of the
mutant ABCG2 proteins (482G-2, 482T-7) had IC50 values that
were again about four-fold higher than for cells expressing wild-
type 482R-5 ABCG2 (data not shown). Both sets of experiments
suggest that mitoxantrone is a better substrate for mutant ABCG2
than wild type. HEK-293 cells expressing any of the ABCG2
proteins demonstrated 21- to 34-fold resistance to topotecan and
48- to 96-fold resistance to SN-38. For either drug, the IC50 of the
482R wild-type clone was higher than that observed in the clones
expressing mutant ABCG2. Cells transfected with wild-type ABCG2
showed little resistance to the anthracyclines doxorubicin and
daunorubicin, as well as bisantrene, epirubicin, and rhodamine
123, compared to mutant ABCG2. ABCG2 conferred low levels of
resistance to etoposide, but did not confer obvious resistance to
depsipeptide or paclitaxel. Surprisingly, none of the ABCG2
proteins conferred appreciable resistance to flavopiridol. This is
in contrast to a previous finding showing resistance to flavopiridol
in selected cell lines overexpressing ABCG2 and overexpression of
ABCG2 in cell lines selected in flavopiridol (Robey et al, 2001b).
Effect of amino-acid 482 mutations on antagonist efficacy
As mutations in Pgp have been shown to affect the ability of Pgp
antagonists to prevent Pgp-mediated efflux (Chen et al, 1997; Ma
et al, 1997; Watanabe et al, 2000), we examined the impact of the
mutations at amino-acid 482 on ABCG2 antagonists. ABCG2-
transfected cells were incubated for 30min in 250nM BODIPY-
prazosin alone, or with 50mM novobiocin, 100mM novobiocin,
100mM b-estradiol, 100mM estrone, or 10mM FTC. Cells were then
washed and incubated for 1h in substrate-free media continuing
without or with the desired blocker to generate the efflux or
inhibitor/efflux histograms, respectively. The FTC/efflux histogram
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Figure 1 Expression of ABCG2 in HEK-293 cells transfected with wild-
type and mutant ABCG2. (A) Northern blot analysis was performed on
20mg RNA extracted from six cell lines transfected with ABCG2 (482G-1,
482G-2, 482R-2, 482R-5, 482T-7, 482T-10) and one cell line transfected
with empty vector (pcDNA3-10) and probed with a riboprobe generated
from the first 662bp of ABCG2. (B) Immunoblot analysis for ABCG2 using
the anti-ABCG2 antibody BXP-21 was performed on membrane protein
(30mg) from the seven transfected cell lines. (C) Immunoblot analysis for
ABCG2 with serial dilutions of membranes isolated from same transfected
clones (482G-1, 482R-2, 482T-10) subsequently used in cytotoxicity assays.
(D) The seven transfected cell lines were incubated for 30min with either
phycoerythrin-labelled negative control antibody (dotted line) or phycoer-
ythrin-labelled anti-ABCG2 antibody (dashed line) and then analysed on a
flow cytometer. Representative histograms are shown.
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maximal accumulation. The values in Table 3 were generated by
subtracting the mean channel number of the inhibitor/efflux
histogram from the FTC/efflux histogram. The more effective the
inhibitor, the smaller the difference between the inhibitor/efflux
histogram and the FTC/efflux histogram. Values in the efflux
column were obtained by subtracting the mean channel value of
the efflux histogram from the FTC/efflux histogram, providing a
measure of ABCG2 activity in each cell line. Both of the 482R
clones show slightly lower BODIPY-prazosin efflux than the
mutant clones, a result that parallels the mitoxantrone cross-
resistance and transport data. The compounds b-estradiol and
estrone (Imai et al, 2002) have also recently been reported to
inhibit ABCG2-mediated transport. We confirm that both com-
pounds do block ABCG2, although b-estradiol appears to be more
effective than estrone.
The ability of the putative ABCG2 antagonist novobiocin (Doyle
et al, 2002; Shiozawa et al, 2002) to block ABCG2-mediated efflux
of BODIPY-prazosin was most affected by the amino acid at
position 482. The difference between the 50mM novobiocin/efflux
histogram and the FTC/efflux histogram was smallest for cells
transfected with wild-type ABCG2, suggesting that novobiocin is
Table 1 Antibody labelling and FTC-inhibitable efflux of fluorescent compounds in ABCG2 transfected cell lines
Cell line 5D3
a BODIPY-prazosin
b Mitoxantrone
b LysoTracker
b Daunorubicin
b Hoechst 33342
b Rhodamine 123
b
482G-1 531.0742.6 314.2721.4 183.3716.6 91.372.1 117.971.2 208.0712.7 241.9718.9
482G-2 504.2741.3 294.7726.1 181.9724.3 77.7710.0 137.36710.2 234.878.2 214.9727.1
482R-2 474.7751.6 186.9741.2 120.6716.5 18.4710.4 4.470.4 164.874.3 0
482R-5 557.2716.4 233.3713.6 16279.8 21.5714.7 12.470.6 212.1716.5 0
482T-7 443.5730.1 259.6718.8 137.3725.8 75.778.6 128.98714.6 216.773.3 238.2713.2
482T-10 471.4718.6 223.3734.9 143.8725.4 85.39716.2 166.376.9 199.675.1 232.4728.2
aThe values calculated are the difference in mean channel numbers between the 5D3 antibody histogram and the negative control antibody histogram.
bDifference in mean
channel number between the FTC/efflux histogram and the efflux histogram. Negative values were assigned the value of zero. Values obtained were from at least two
independent experiments.
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Figure 2 Transport of fluorescent substrates by wild-type and mutant ABCG2. The six transfected cell lines were incubated in rhodamine 123
(0.5mgml
1), daunorubicin (5mgml
1), mitoxantrone (20mM), BODIPY-prazosin (250nM), or LysoTracker Green (250nM) with or without 10mM FTC for
30min at 371C. Cells were then washed, allowed to efflux for 1h at 371C in substrate-free media continuing with (dotted line) or without (solid line) FTC,
and analysed on a flow cytometer. Representative results are shown. Mean channel differences from 2 or more experiments are present in Table 1.
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shown in Table 3. Efflux mediated by the mutant ABCG2 proteins
was nearly unaffected by novobiocin. Increasing the concentration
of novobiocin to 100mM almost completely abrogated wild-type
ABCG2-mediated efflux. Histograms for the transfectants are
shown in Figure 4A. BODIPY-prazosin fluorescence in the presence
of 50mM novobiocin (dotted line) in HEK-293 cells transfected with
wild-type ABCG2 was comparable to that in cells incubated with
10mM FTC (dashed line). For 482R-5, these histograms overlap.
However, novobiocin was less effective in mutant 482G and 482T
ABCG2, where BODIPY-prazosin accumulation with novobiocin is
near that of cells incubated with BODIPY-prazosin alone (solid line).
To verify the flow cytometry results, 4-day cytotoxicity assays
were then performed on HEK-293 cells transfected with wild-type
and mutant ABCG2 in the presence of topotecan with (filled
symbols) and without (open symbols) 50mM novobiocin as shown in
Figure 4B. Topotecan was selected because cross-resistance studies
(in Table 2) suggested that cells transfected with wild-type ABCG2
exhibited slightly higher resistance to the drug compared to the
mutant proteins. In empty vector transfected cells (squares) as well
as the mutant 482G-1 and 482T-10 cells (circles), 50mM novobiocin
had little effect on topotecan cytotoxicity. Cells transfected with
482G ABCG2 were 21-fold resistant to topotecan (filled circles) and
14-fold resistant in the presence of 50mM novobiocin (open circles),
while cells transfected with 482T ABCG2 were 29-fold resistant to
topotecan (filled circles) and were nine-fold resistant to the drug in
the presence of novobiocin (open circles). In contrast, HEK-293 cells
transfected with wild-type ABCG2 (482R) were 71-fold resistant to
topotecan (filled circles), and were only three-fold resistant to the
drug in the presence of 50mM novobiocin. Thus, novobiocin nearly
completely reversed wild-type ABCG2-mediated resistance to topo-
tecan. Dose-modifying factors (DMFs) were also calculated for each
transfectant by dividing the IC50 for topotecan alone by the IC50 of
topotecan in the presence of novobiocin and are given in Figure 4B.
DISCUSSION
To confirm earlier transport and resistance studies conducted with
selected cell lines overexpressing wild-type and mutant ABCG2
(Honjo et al, 2001; Robey et al, 2001a), HEK-293 cells were
transfected with vectors encoding wild-type or mutant ABCG2.
Our results with these transfectants confirm that the fluorescent
compounds mitoxantrone, BODIPY-prazosin, and Hoechst 33342
are substrates of all three ABCG2 proteins tested in the present
study, while LysoTracker Green, daunorubicin, and rhodamine 123
are only appreciably transported by the mutant 482G and 482T
proteins. In cytotoxicity assays, all ABCG2 proteins conferred high
levels of resistance to mitoxantrone, topotecan, and SN-38, while
the mutant proteins conferred four times more resistance to
mitoxantrone than the wild-type protein. Cells transfected with
wild-type ABCG2 appeared slightly more resistant to SN-38 and
topotecan. The mutant 482G and 482T ABCG2 proteins conferred
Table 2 Cross-resistance profile of HEK-293 cells transfected with wild-type and mutant ABCG2
pcDNA3 482G-1 482R-2 482T-10
Drug IC50 (nM)I C 5 0 ( n M)R R
a IC50 (nM) RR IC50 (nM)R R
Mitoxantrone 3.871.8 543753 140 107764 28 4577287 118
Topotecan 872 175750 22 275750 34 167765 21
SN-38 1.271.1 65735 52 1207113 96 60742 48
Doxorubicin 11.276.3 5757171 51 35713 3 8007245 71
Daunorubicin 2070.1 200711 0 4 0 71 2 333758 17
Bisantrene 127764 16677577 13 6337115 5 16677577 13
Epirubicin 2577.1 6007141 24 9577.1 4 7007424 28
Paclitaxel 9712 0 712 3 0 714 3 30713
Depsipeptide 4716 71 1.5 871 2 7.5712
Flavopiridol 123768 200710 2 160769 1 200710 2
Etoposide 7577 650771 9 250771 3 4507212 6
Rhodamine 123 700072000 2670007115000 38 53000712000 8 267000758000 38
aRelative resistance values were obtained by dividing the IC50 value of the ABCG2-transfected cell lines by the IC50 value of the empty vector transfected cell line. Values
obtained were from two to five separate experiments.
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Figure 3 Cross-resistance profile conferred by wild-type and mutant
ABCG2. The 4-day cytotoxicity assays were performed with mitoxantrone,
SN-38, topotecan, daunorubicin, etoposide, and flavopiridol on HEK-293
cells transfected with empty vector (filled squares), or transfected with
482R (hatched squares), 482G (open circles), or 482T (open triangles)
ABCG2. Curves representative of two to five separate experiments are
shown.
Resistance profile of wild-type and mutant ABCG2
RW Robey et al
1975
British Journal of Cancer (2003) 89(10), 1971–1978 & 2003 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s10- to 71-fold resistance to the Pgp substrates doxorubicin,
daunorubicin, and epirubicin. In contrast, wild-type 482R ABCG2
conferred only three- to four-fold resistance to these agents. Thus,
while flow cytometric analysis suggests no transport of daunor-
ubicin or rhodamine 123 in cells transfected with wild-type
ABCG2, cross-resistance studies do suggest that wild-type ABCG2
confers a very low level of resistance to these two compounds. All
three ABCG2 proteins conferred low levels of resistance to
etoposide, while no appreciable resistance to paclitaxel, depsipep-
tide or flavopiridol was noted.
Mutations at amino-acid 482 have included R482G and R482T
in human cancer cells; R482S and R482M in mouse fibroblast
lines (Honjo et al, 2001; Allen et al, 2002); and a recently
reported R482M mutation in a doxorubicin-selected human T-cell
line (Wang et al, 2003). Since amino-acid 482 is predicted to
be at the beginning of the third transmembrane segment
on the intracellular surface of the membrane, it could be directly
involved in substrate binding or could affect substrate transport
through structural alterations in the third transmembrane
segment (Honjo et al, 2001). Although Allen et al (2002) have
suggested that loss of the basic arginine at amino-acid 482 may be
critical to substrate specificity, mechanistic studies are needed
to understand the changes that result from alteration at amino-
acid 482.
Since the wild-type arginine is a bulky, positively charged amino
acid, it could impede binding or transport of positively charged
compounds. While this could explain the poor transport of
doxorubicin and daunorubicin, both of which possess aliphatic
amino groups that are positively charged at a physiological pH
(7.6), we would note that mitoxantrone, a substrate for all ABCG2
proteins, has a similar structure and charge. LysoTracker and
BODIPY-prazosin both carry a positive charge on a boron atom,
thus resembling rhodamine’s positively charged amino group, yet
only prazosin is a substrate for all three ABCG2 proteins. These
observations suggest that a positive charge alone is not predictive
of whether a compound will be an ABCG2 substrate.
Table 3 Inhibition of BODIPY-prazosin efflux in ABCG2 transfectants assayed by flowcytometry
100lM b-estradiol
a 100lM estrone
a 50lM Novobiocin
a 100lM Novobiocin
a Efflux
b
482G-1 65.377.6 107.879.9 221.979.8 161.178.6 264.3718.3
482G-2 90.5715.7 116.2715.7 279.6735.1 199.9719.0 301.479.1
482R-2 44.972.5 73.671.4 97.3713.6 47.672.0 163.0710.3
482R-5 62.873.9 82.272.5 132.6724.6 58.078.9 218.2711.1
482T-7 78.5748.8 88.279.9 279.3713.7 242.4757.5 284.0726.3
482T-10 87.475.7 104.8720.2 236.879.0 216.6738.5 263.178.7
aThe values shown are the difference in mean channel numbers between the FTC/efflux histogram and the inhibitor/efflux histogram of the noted inhibitor.
bDifference in mean
channel number between the FTC/efflux histogram and the efflux histogram. Values were obtained from two separate experiments.
0
25
50
75
100
125
0
20
40
60
80
100
0
25
50
75
100
125
%
 
S
u
r
v
i
v
a
l
0.0010.01 0.1 1 10
482G
DMF = 1.5
482T
DMF = 3
482R
DMF = 24
Topotecan (M)
0.0010.01 0.1 1 10
0.0010.01 0.1 1 10
0
0
50
200 400 600 8001000
0
50
0
40
0
30
0
40
0
40
4
8
2
T
-
1
0
4
8
2
T
-
7
4
8
2
R
-
5
4
8
2
R
-
2
4
8
2
G
-
2
4
8
2
G
-
1
C
o
u
n
t
s
0 200 400 600 8001000
0 200 400 600 8001000
0 200 400 600 8001000
0 200 400 600 8001000
0 200 400 600 8001000
A
B
BODIPY-prazosin fluorescence
Figure 4 Novobiocin reverses wild-type ABCG2 but not mutant ABCG2-mediated resistance. (A) The six transfected cell lines were incubated in 250nM
BODIPY-prazosin with or without 50mM novobiocin for 30min at 371C, washed, then allowed to efflux for 1h at 371C continuing with (dotted line) or
without (solid line) novobiocin and compared to cells incubated in 10mM FTC (dashed line). (B) The 4-day cytotoxicity assays were performed with
topotecan with (filled symbols) or without (open symbols) 50mM novobiocin on HEK-293 cells expressing wild-type (482R) or mutant (482G, 482T)
ABCG2 as detailed in the Materials and Methods section. Representative results are shown. Empty vector transfected cells are shown as squares while
ABCG2 transfected cells are denoted by circles. Dose-modifying factor values were obtained for the ABCG2-transfected cells by dividing the IC50 for
topotecan without novobiocin by the IC50 value for topotecan in the presence of novobiocin.
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shown to be affected by mutations in ABCG2 at amino-acid 482.
Volk et al report that selected cell lines expressing wild-type ABCG2
are resistant to methotrexate. Loss of the positive charge at amino-
acid 482 by mutation to glycine or threonine yields a protein
conferring much less resistance to the drug (Volk et al,2 0 0 2 ) .I t
seems reasonable to assume that mutations at amino-acid 482 in
ABCG2 could affect the ability of the protein to confer resistance to
other drugs currently being evaluated for use in the clinic.
The findings presented here parallel those of Allen et al, (2002),
who described two mutations, R482M and R482S, in mouse
fibroblast cells lacking functional Mdr1, Mdr2, and Mrp1. These
authors observed greater anthracycline resistance, lower topotecan
resistance and enhanced transport of rhodamine 123. Unlike our
observations in human cells where a change from arginine to
glycine or threonine occurred early in the course of the drug
selection, in the mouse fibroblasts selected with doxorubicin,
overexpression and amplification of wild-type Abcg2 occurred
before mutation at amino-acid 482. This would suggest that
murine Abcg2 can confer biologically meaningful resistance to
doxorubicin; a finding that appears to be in conflict with the very
low levels of resistance we observed in HEK-293 cells transfected
with wild-type human ABCG2. This may simply be due to differing
substrate affinities in the ABCG2 protein in the two species, as has
been reported for MRP1 (Stride et al, 1997).
Mutations at amino-acid 482 also were found to alter the efficacy
of a reported ABCG2 inhibitor. Novobiocin, a compound recently
reported to block ABCG2-mediated efflux (Doyle et al, 2002;
Shiozawa et al, 2002), was found to be most effective on wild-type
ABCG2 and nearly ineffective on mutant ABCG2. This would
suggest that, if the described R482T or R482G mutations in ABCG2
were to occur in patients, they could render currently known
ABCG2 inhibitors less effective. FTC at 10mM appeared to inhibit
all of the ABCG2 proteins equally well. Both b-estradiol and
estrone inhibited ABCG2-mediated prazosin transport; however,
estrone was the least effective of the two.
It was surprising that the transfected cells displayed no
resistance to flavopiridol, since we have reported overexpression
of ABCG2 in cells selected with flavopiridol and have shown cross-
resistance to flavopiridol in ABCG2 overexpressing selected cell
lines (Robey et al, 2001b). This could be due to the fact that
flavopiridol is a substrate with a weak affinity to ABCG2 and thus
the expression of ABCG2 in the transfected cells is inadequate to
confer appreciable resistance. In support of this explanation is the
cross-resistance data obtained in a cell line selected in flavopiridol
(MCF-7 FLV1000) which was only 24-fold resistant to flavopiridol
but was 675-fold resistant to mitoxantrone. Alternatively, mod-
ification of flavopiridol may be necessary to allow it to be better
transported. Recent studies have shown that flavopiridol is most
likely glucuronidated in human liver by UDP-glucuronosyltrans-
ferase isoforms (Ramirez et al, 2002). We have previously
suggested a link between glucuronidation and resistance mediated
by ABCG2, as we noted increased expression of UDP-glucurono-
syltransferase in cell lines that overexpress ABCG2 (Brangi et al,
1999). It is thus possible that breast carcinoma cells
selected in flavopiridol have the capacity to glucuronidate
flavopiridol, while HEK-293 cells do not. Studies are currently
underway to determine if flavopiridol-selected cells do indeed
glucuronidate flavopiridol in order to transport it.
In summary, we show that mutation of a single amino acid in
the ABCG2 protein has a major effect on its substrate specificity,
and may possibly undermine the effectiveness of potential ABCG2
blockers.
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